Sun Pharma (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Sun Pharmaceutical Industries Limited |
|||
|
Price: ₹1,786.55 (+1.32%) | ||
| 52 Week Low: ₹1,290.00 52 Week High: ₹1,960.35 |
|||
| Market Capital: 3,58,724.35 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Sun Pharma Share Price Target For 2025
- 1.1.1: Sun Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Sun Pharma Share Price Target For 2026
- 1.2.1: Sun Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Sun Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Sun Pharma Brief Company Overview
- 4: Sun Pharma Financial Performance
- 4.0.1: Is Sun Pharma A Good Buy For Long Term?
Sun Pharma, a Large Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 333.1% returns in 5-year showing 9.6% quarterly revenue growth with 19.7% profit margin, making it a potential Multibagger.
To predict the Sun Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Sun Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Sun Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sun Pharma shares in 2025, see the table below.
Sun Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1914.7 (+7.17%) | Price Action: 16 Oct 2024 High |
| 2025 Target 2 | 1894.5 (+6.04%) | Price Action: 09 Oct 2024 Low |
| 2025 Target 1 | 1875.0 (+4.95%) | Price Action: 23 Sep 2024 High |
| Current Price | 1786.55 | Sun Pharma's share price as of 17 Jan 2025 |
| Stop Loss 1 | 1746.45 (-2.25%) | Price Action: 01 Aug 2024 High |
| Stop Loss 2 | 1728.75 (-3.24%) | Price Action: 29 Jul 2024 High |
| Stop Loss 3 | 1709.4 (-4.32%) | Price Action: 07 Aug 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Sun Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹1805.89 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.37% | 6-month: +3.91% | 1-year: +27.07%
Sun Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Sun Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sun Pharma shares in 2026, see the table below.
Sun Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 2539.54 (+42.14%) | Price Action: Chart |
| 2026 Target 2 | 2492.19 (+39.49%) | Price Action: Chart |
| 2026 Target 1 | 2467.51 (+38.11%) | Fibonacci Extension Level 64.90% |
| Current Price | 1786.55 | Sun Pharma's share price as of 17 Jan 2025 |
| Stop Loss 1 | 1628.83 (-8.83%) | Price Action: Mar 2024 High |
| Stop Loss 2 | 1609.6 (-9.91%) | Price Action: 26 Mar 2024 High |
| Stop Loss 3 | 1592.0 (-10.89%) | Price Action: 24 Jul 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Sun Pharma is currently trading at 74.1% of its 52-week range (₹1290 - ₹1960.35).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +27.07% | 3-year: +120.83% | 5-year: +333.07%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Sun Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,786.55 | ||
| 2025 | ₹2,701.23 | +51.19% | ₹2,741.75 |
| 2026 | ₹3,358.97 | +24.34% | ₹3,409.35 |
| 2027 | ₹4,656.14 | +38.61% | ₹4,725.98 |
| 2028 | ₹6,092.33 | +30.84% | ₹6,183.71 |
| 2029 | ₹8,203.82 | +34.65% | ₹8,326.88 |
| 2030 | ₹9,488.15 | +15.65% | ₹9,630.47 |
| 2031 | ₹12,393.89 | +30.62% | ₹12,579.80 |
| 2032 | ₹14,254.90 | +15.01% | ₹14,468.72 |
| 2033 | ₹18,056.65 | +26.66% | ₹18,327.50 |
| 2034 | ₹21,197.68 | +17.39% | ₹21,515.65 |
| 2035 | ₹24,759.67 | +16.8% | ₹25,131.07 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Sun Pharma Brief Company Overview
Sun Pharmaceutical Industries Limited: A Pharmaceutical Powerhouse Sun Pharmaceutical Industries Limited is a renowned generic pharmaceutical company with a global reach. Established in 1983, the company has become a leading provider of branded and generic...
formulations, as well as active pharmaceutical ingredients (APIs). Sun Pharma's product portfolio covers a wide spectrum of therapeutic areas, including cardiology, neuropsychiatry, oncology, gastroenterology, and many more. The company also offers speciality medications, anti retro viral medications, and over-the-counter products. With a commitment to innovation and customer satisfaction, Sun Pharma has earned a strong reputation in the industry. Its diverse product range, global presence, and unwavering commitment to quality have made it a trusted partner for healthcare professionals and patients alike.Sun Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 3,58,724.35 Crore | Market valuation of Sun Pharma's shares. |
| Revenue (TTM) | 48,496.84 Crore | Total revenue generated by Sun Pharma over the past twelve months. |
| Net Income (TTM) | +9,576.38 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +20.37% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.73% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+9.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+33.79% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
4.87 | Company's total debt divided by total shareholder equity. |
| Total Debt | 3,273.67 Crore | Sum of Sun Pharma's current & long-term financial obligations. |
| Total Cash | 19,105.22 Crore | Total amount of liquid funds available to Sun Pharma. |
| Beta | 0.52 | Beta is less than 1 indicating that the Sun Pharma's price is less volatile than the market. |
Is Sun Pharma A Good Buy For Long Term?
Sun Pharma, a large-cap stock with consistent revenue growth (9.6% QoQ) and profitability (33.8% YoY earnings growth), appears to be a promising investment for the long term. Its healthy profit margin (19.74%) and strong financial position with ample cash reserves of 19,105.22 Crore indicate the company's financial strength. While it does have some debt (3,273.67 Crore), its strong cash position mitigates any concerns. Overall, the company's impressive financial performance, coupled with its strong fundamentals, make it a suitable choice for long-term investors seeking steady growth and potential returns.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
